Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Valganciclovir Hydrochloride

FDA-approved product (tablet, oral), marketed as Valcyte, Valganciclovir Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Valganciclovir Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • AIDS
  • Cytomegalovirus Retinitis
  • Retinitis
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB14

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Valganciclovir Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Valganciclovir Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

    NCT02871401 · start 2018-01-03

    Registered record
    Registry ID
    NCT02871401
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    Valganciclovir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-03
    Completion
    2020-01-31
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionValganciclovir; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance

    NCT02606266 · start 2017-07-11

    Registered record
    Registry ID
    NCT02606266
    Conditions
    Congenital Cytomegalovirus (CMV)
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2017-07-11
    Completion
    2018-12-11
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Cytomegalovirus (CMV)
    InterventionValganciclovir
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population

    NCT02973464 · start 2016-06

    Registered record
    Registry ID
    NCT02973464
    Conditions
    Renal Transplant Recipients
    Interventions
    Valganciclovir; Ganciclovir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2019-12
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplant Recipients
    InterventionValganciclovir; Ganciclovir
    PhaseNot recorded
    Registry statusUnknown

  • Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center

    NCT02409147 · start 2016-01

    Registered record
    Registry ID
    NCT02409147
    Conditions
    Uterus Transplant
    Interventions
    Uterine Transplant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2016-01
    Completion
    2018-07-24
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterus Transplant
    InterventionUterine Transplant
    PhaseNot applicable
    Registry statusWithdrawn

  • A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

    NCT02439970 · start 2015-09

    Registered record
    Registry ID
    NCT02439970
    Conditions
    Cytomegalovirus Disease
    Interventions
    Brincidofovir; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2016-01-30
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Disease
    InterventionBrincidofovir; Valganciclovir
    PhasePhase 3
    Registry statusTerminated

  • Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

    NCT01649869 · start 2015-02-24

    Registered record
    Registry ID
    NCT01649869
    Conditions
    Cytomegalovirus Infection
    Interventions
    Placebo; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02-24
    Completion
    2019-12-24
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infection
    InterventionPlacebo; Valganciclovir
    PhasePhase 2
    Registry statusCompleted

  • Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients

    NCT02503982 · start 2014-12

    Registered record
    Registry ID
    NCT02503982
    Conditions
    Infection in Solid Organ Transplant Recipients
    Interventions
    prophylactic Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-12
    Completion
    2015-08
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection in Solid Organ Transplant Recipients
    Interventionprophylactic Valganciclovir
    PhasePhase 4
    Registry statusCompleted

  • GEN2 Directed Cancer Immunotherapy Trial

    NCT04313868 · start 2014-06-13

    Registered record
    Registry ID
    NCT04313868
    Conditions
    Hepatocellular Carcinoma; Metastatic Cancer
    Interventions
    GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-06-13
    Completion
    2023-12-12
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma; Metastatic Cancer
    InterventionGEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
    PhasePhase 1
    Registry statusCompleted

  • Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial

    NCT01655212 · start 2012-06

    Registered record
    Registry ID
    NCT01655212
    Conditions
    Congenital Cytomegalovirus Infection; Sensorineural Hearing Loss
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-06
    Completion
    2013-10
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Cytomegalovirus Infection; Sensorineural Hearing Loss
    InterventionValganciclovir
    PhasePhase 3
    Registry statusTerminated

  • Cytomegalovirus Control in Critical Care

    NCT01503918 · start 2012-01

    Registered record
    Registry ID
    NCT01503918
    Conditions
    Critical Illness
    Interventions
    Valaciclovir/Aciclovir; Valganciclovir/Ganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-01
    Completion
    2014-03
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness
    InterventionValaciclovir/Aciclovir; Valganciclovir/Ganciclovir
    PhasePhase 2
    Registry statusCompleted

  • Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection

    NCT01509404 · start 2011-11

    Registered record
    Registry ID
    NCT01509404
    Conditions
    Cytomegalovirus Disease
    Interventions
    Valganciclovir; CMV hyperimmune globulin; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-11
    Completion
    2015-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Disease
    InterventionValganciclovir; CMV hyperimmune globulin; Valganciclovir
    PhasePhase 4
    Registry statusCompleted

  • Tocilizumab for KSHV-Associated Multicentric Castleman Disease

    NCT01441063 · start 2011-09-13

    Registered record
    Registry ID
    NCT01441063
    Conditions
    Castleman Disease; Multicentric Castleman Disease; Giant Lymph Node Hyperplasia
    Interventions
    Zidovudine; Tocilizumab; Valganciclovir (VGC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09-13
    Completion
    2020-10-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastleman Disease; Multicentric Castleman Disease; Giant Lymph Node Hyperplasia
    InterventionZidovudine; Tocilizumab; Valganciclovir (VGC)
    PhasePhase 2
    Registry statusCompleted

  • Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

    NCT01419561 · start 2011-09-08

    Registered record
    Registry ID
    NCT01419561
    Conditions
    KSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8
    Interventions
    Zidovudine; Liposomal Doxorubicin; Valganiclovir; Rituximab; Standard Therapies; Cohort 1
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2011-09-08
    Completion
    2028-12-31
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8
    InterventionZidovudine; Liposomal Doxorubicin; Valganiclovir; Rituximab +2 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

    NCT01376804 · start 2011-07-31

    Registered record
    Registry ID
    NCT01376804
    Conditions
    Kidney Transplantation, Cytomegalovirus Infections
    Interventions
    valganciclovir [Valcyte]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-07-31
    Completion
    2013-05-31
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplantation, Cytomegalovirus Infections
    Interventionvalganciclovir [Valcyte]
    PhasePhase 4
    Registry statusCompleted

  • Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition

    NCT02297854 · start 2011-07

    Registered record
    Registry ID
    NCT02297854
    Conditions
    Healthy
    Interventions
    Valganciclovir Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07
    Completion
    2011-08
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionValganciclovir Hydrochloride
    PhasePhase 1
    Registry statusCompleted